Profound Medical Corp.
PROF
$6.32
-$0.11-1.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.75M | 2.71M | 2.83M | 2.44M | 1.38M |
| Total Other Revenue | 10.07M | 8.66M | 8.56M | 8.20M | 7.56M |
| Total Revenue | 13.83M | 11.37M | 11.39M | 10.21M | 8.51M |
| Cost of Revenue | 3.90M | 3.59M | 3.81M | 3.61M | 3.45M |
| Gross Profit | 9.93M | 7.78M | 7.59M | 6.60M | 5.06M |
| SG&A Expenses | 31.56M | 30.76M | 26.49M | 23.07M | 22.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.47M | 54.10M | 48.16M | 43.69M | 42.05M |
| Operating Income | -42.64M | -42.73M | -36.77M | -33.48M | -33.53M |
| Income Before Tax | -39.74M | -41.07M | -32.34M | -28.21M | -31.53M |
| Income Tax Expenses | -12.00K | 44.00K | -1.00K | -2.00K | 7.00K |
| Earnings from Continuing Operations | -39.73 | -41.12 | -32.34 | -28.20 | -31.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.73M | -41.12M | -32.34M | -28.20M | -31.53M |
| EBIT | -42.64M | -42.73M | -36.77M | -33.48M | -33.53M |
| EBITDA | -41.82M | -41.84M | -35.78M | -32.40M | -32.59M |
| EPS Basic | -1.35 | -1.47 | -1.23 | -1.14 | -1.34 |
| Normalized Basic EPS | -0.85 | -0.92 | -0.77 | -0.71 | -0.84 |
| EPS Diluted | -1.35 | -1.47 | -1.23 | -1.14 | -1.34 |
| Normalized Diluted EPS | -0.85 | -0.92 | -0.77 | -0.71 | -0.84 |
| Average Basic Shares Outstanding | 115.97M | 110.40M | 104.79M | 99.04M | 94.64M |
| Average Diluted Shares Outstanding | 115.97M | 110.40M | 104.79M | 99.04M | 94.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |